Pfizer (PFE) Heads Into Its London Conference, Is The Stock Fully Priced?

Pfizer (PFE) is heading into its U.S. All Stars Conference appearance in London on 22 September 2026 with investors weighing its shareholder payouts, recent acquisitions, and ongoing legal and pipeline developments.

Pfizer’s share price has gathered some momentum into the conference, with a 90-day share price return of 18.03% and a year-to-date share price return of 13.86%, while the 1-year total shareholder return of 29.13% contrasts with a 5-year total shareholder return that remains in decline at 12.99%.

Compare Pfizer's recent rebound with curated healthcare peers by scanning our 38 healthcare AI stocks, which blend medical focus with AI driven pipelines and infrastructure.

The recent rebound in Pfizer raises a simple issue for anyone looking at the stock today. Does the current price still leave enough upside to justify the risks investors are taking from here?

Most Popular Narrative: 70% Undervalued

The most followed Pfizer narrative puts fair value at $28.88, which sits very close to the last close of $28.67, yet still frames the current price as baking in a cautious outlook that leans heavily on future execution.

Expansion of launched and acquired products, including Seagen and Biohaven portfolios that generated US$3.2b of Q2 2026 revenue and grew at double digit rates, supports the view that Pfizer can further shift its mix toward non COVID therapies and sustain revenue beyond loss of exclusivity periods.

See why 534 investors see Pfizer as 1% undervalued.

Result: Fair Value of $28.88 (UNDERVALUED)

Still, two pressure points could easily upset this Pfizer story: tougher drug pricing rules that squeeze margins, and any further clinical or portfolio setbacks.

Find out about the key risks to this Pfizer narrative.

Next Steps

If this combination of optimism and caution around Pfizer feels familiar, consider evaluating it now while the information is fresh in your mind, and pressure test it yourself using our breakdown of 2 key rewards and 4 important warning signs

Looking for more ideas beyond Pfizer?

Before moving on, lock in your momentum by lining up a few fresh opportunities that match your risk appetite and income goals.

• Target steadier portfolio candidates by scanning a 30 resilient stocks with low risk scores built to highlight businesses with more resilient risk scores.
• Hunt for potential bargains by reviewing a 16 high quality undiscovered gems that filters for quality fundamentals hiding outside the usual headlines.
• Strengthen your income stream by focusing on 8 dividend fortresses so you are not relying on price moves alone for returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com